<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03604796</url>
  </required_header>
  <id_info>
    <org_study_id>0207-18-SZMC</org_study_id>
    <nct_id>NCT03604796</nct_id>
  </id_info>
  <brief_title>Alternative Paracetamol Treatments for the Neonate With a hsPDA</brief_title>
  <official_title>Alternative Acetaminophen Treatment of the Hemodynamivally Significant Patent Ductus Arteriosus in Preterm Neonates Who Are Not Candidates for Enteral Administration: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shaare Zedek Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shaare Zedek Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Early targeted treatment of a hemodynamically significant patent ductus arteriosus (hsPDA)
      during the first week of life in preterm neonates is often recommended. Our standard first
      line therapeutic approach is enteral acetaminophen. However many extremely low birth weight
      infants may be on limited or no feeds when PDA closure is determined to be indicated, thus
      restricting the use of enteral acetaminophen. Several studies have suggested that intravenous
      acetaminophen is less effective than enteral. Thus, in this study, we propose to compare two
      alternative modes of administration when enteral acetaminophen is not an option.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Once parental consent for entrance into the study is obtained, eligible babies will be
      randomized to receive either IV acetaminophen (perfalgen) by continuous infusion at 2.5
      mg/kg/h following a loading dose of 15 mg /kg/ over 20 minutes or rectal acetaminophen at 15
      mg/kg every 6 hours for a period of 3 days.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2018</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ductal closure</measure>
    <time_frame>Up to 1 week following treatment</time_frame>
    <description>Follow-up echocardiogram showing closed ductus arteriosus</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PDA Ligation</measure>
    <time_frame>Completion of study intervention until 40 weeks post-conception</time_frame>
    <description>Need for surgical ligation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Ductus Arteriosus, Patent</condition>
  <arm_group>
    <arm_group_label>Continuous IV Acetaminophen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous Infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rectal Acetaminophen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rectal Solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rectal Solution</intervention_name>
    <description>Rectal acetaminophen at 15 mg/kg x 4/day for three days</description>
    <arm_group_label>Rectal Acetaminophen</arm_group_label>
    <other_name>acetaminophen / paracetamol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous Infusion</intervention_name>
    <description>Loading dose of 15 mg/kg IV acetaminophen followed by a continuous infusion at a rate of 2.5 mg/kg/hr for 72 hours</description>
    <arm_group_label>Continuous IV Acetaminophen</arm_group_label>
    <other_name>acetaminophen / paracetamol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Inborn preterm neonates, &lt; 1000 gm birth weight; &lt; 28 weeks' gestational age; who are
        admitted to the neonatal intensive care unit of the Shaare Zedek Medical Center and are
        diagnosed with a hemodynamically significant patent ductus arteriosus within the first week
        of life and who are on limited or no enteral feeds -

        Exclusion Criteria:

        Other congenital heart disease, major congenital anomalies, sepsis; and/or NEC.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>10 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cathy Hammerman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shaare Zedek Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cathy Hammerman, MD</last_name>
    <phone>0508685238</phone>
    <email>cathyh@ekmd.huji.ac.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alona Bin-Nun, MD</last_name>
    <phone>0508685757</phone>
    <email>alonabinnun@szmc.org.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Neonatal Intensive Care Unit - Shaare Zedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>91031</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>July 19, 2018</study_first_submitted>
  <study_first_submitted_qc>July 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2018</study_first_posted>
  <last_update_submitted>July 19, 2018</last_update_submitted>
  <last_update_submitted_qc>July 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acetaminophen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ductus Arteriosus, Patent</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

